ryanc97
Senior Member (Voting Rights)
Daratumumab induces mechanisms of immune activation through CD38+ NK cell targeting - Leukemia
Daratumumab (Dara), a multiple myeloma (MM) therapy, is an antibody against the surface receptor CD38, which is expressed not only on plasma cells but also on NK cells and monocytes. Correlative data have highlighted the immune-modulatory role of Dara, despite the paradoxical observation that...
www.nature.com
scihub link - https://sci-hub.hlgczx.com/10.1038/s41375-020-0810-4
"Correlative data have highlighted the immunemodulatory role of Dara, despite the paradoxical observation that Dara regimens decrease the frequency of total NK cells.Here we show that, despite this reduction, NK cells play a pivotal role in Dara anti-MM activity. CD38 on NK cells isessential for Dara-induced immune modulation, and its expression is restricted to NK cells with effector function."
This paper is saying somehow, the CD38+ NK cells that get depleted by Dara via fraticide are also important to the anti-MM activity. However Im not sure exactly how.
Last edited:
